Chembio Diagnostics Names John Sperzel CEO, Effective March 13 - Quick Facts

(RTTNews) - Chembio Diagnostics, Inc. (CEMI) a leader in point-of-care diagnostic tests for infectious diseases, Friday announced the appointment of John Sperzel as President and CEO, effective March 13.

Sperzel succeeds Lawrence Siebert, who has served the company as CEO for over ten years. In September 2013, Siebert announced his plan to retire from Chembio.

Sperzel is an experienced executive in both private and public companies. His career includes over 25 years in the In Vitro Diagnostic market with extensive experience in Point of Care or POC testing.

Most recently, Sperzel served as President and CEO of International Technidyne Corp. or ITC, a privately-held POC diagnostic company.

While at ITC, he led a corporate turnaround which won the 2012 "Most Dramatic Transformation" award among Warburg Pincus-owned Healthcare companies. He also led the acquisition of Accriva Diagnostics, which strengthened ITC's leadership position in POC Cardiovascular diagnostics.

Previously, Sperzel served as President at Axis-Shield where he built a successful commercial team that delivered rapid revenue growth in the United States POC market. He also held senior leadership positions at Bayer Diagnostics, Instrumentation Laboratory and Boehringer Mannheim Diagnostics.